ScreenerHero

EFTR eFFECTOR Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · effector.com
0.0002USD0.00%Mkt Cap: 940 $P/E: —

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap940 USD
Enterprise Value-5.13M USD
Revenue (TTM)—
Gross Profit-21.62M USD
Net Income (TTM)-35.81M USD
Revenue/Share—
Last Price0.0002 USD
Fiscal Year EndDec 2023
MR QuarterMar 2024
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
EV/EBITDA0.16
EV/Revenue—
P/S—
P/B0.00
EPS (TTM)-12.78
EPS (Forward)-2.25
52W Range
0.00020% of range0.0100
52W High0.0100 USD
52W Low0.0002 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE617.96%
ROA-174.31%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.55M USD
CapEx (TTM)97.00K USD
FCF Margin—
FCF Yield-1879348.51%
Net Debt-5.13M USD
Net Debt/EBITDA0.16
Balance Sheet
Debt/Equity-3.55
Current Ratio1.03
Quick Ratio0.99
Book Value/Sh0.21 USD
Cash/Share5.40 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateJan 12, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.70M
Float4.67M
Insiders0.00%
Institutions0.00%
Short Interest
Short Ratio0.5d
Short % Float14.74%
Short % Out.14.60%
Shares Short686.98K
Short (prev mo.)94.71K
Technical
SMA 500.0004 (-49.2%)
SMA 2000.0003 (-39.8%)
Beta2.74
S&P 52W Chg16.45%
Avg Vol (30d)3.80K
Avg Vol (10d)879
Technical Indicators
RSI (14)34.0
MACD0.0000
MACD Signal0.0001
MACD Hist.-0.0001
BB Upper0.0011 USD
BB Middle0.0006 USD
BB Lower0.0001 USD
BB Width157.59%
ATR (14)0.0001 USD
Vol Ratio (20d)0.00x